The discovery that gut bacteria actively regulate arterial inflammation challenges the lipid-centric model of heart disease that has dominated cardiovascular medicine for decades. This emerging paradigm suggests that microbial communities in our intestines function as a biological control system for vascular health, potentially explaining why traditional cholesterol management fails to prevent all cardiovascular events. The research reveals that specific bacterial metabolites act as either inflammatory triggers or protective agents in arterial disease. Harmful compounds like trimethylamine N-oxide and imidazole propionate promote atherosclerotic plaque formation, while certain tryptophan derivatives appear to shield arteries from damage. The mechanism involves pathogen-associated molecular patterns that activate chronic inflammatory cascades in blood vessels. Particularly striking is evidence that oral cavity bacteria migrate to the gut in cardiovascular disease patients, suggesting that dental health and heart health share common microbial pathways. The gut microbiome also influences how the body processes and stores lipids, creating a complex interplay between microbial metabolism and traditional cardiovascular risk factors. This bacterial involvement extends to vascular aging processes, indicating that microbiome health may influence arterial function throughout the lifespan. While preclinical studies show promise for microbiome-targeted interventions including specific probiotics and prebiotics, human clinical evidence remains limited. The field represents a significant shift toward personalized cardiovascular prevention based on individual microbiome profiles rather than solely lipid markers, though translating these insights into clinical practice requires substantially more human research.